BioNTech Receives FDA Approval for 5 – 11 Years Old

Vaccine studies around the world continue unabated, and the agenda is now focused on vaccination studies and third dose applications in children. Research on the vaccination of children in the USA gained momentum. In this context, the BioNTech vaccine was administered last week. Children aged 5 to 11 years It was announced that it was 90.7 percent effective.

Now, the US Federal Food and Drug Administration (FDA) has taken a big step and approved the use of BioNTech between the ages of 5 and 11. This decision will pave the way for the vaccination of approximately 28 million children in the USA. development, especially in schools. The effect of face-to-face education on the number of cases It is stated that there is an important development regarding the course of the epidemic at a time when it is discussed.

‘The decision will bring us closer to returning to normal’

Making a statement on the subject, FDA official Dr. Janet Woodcock”As a mother and doctor, I know that parents, caregivers, school staff and children await this leave. Smaller Vaccinating children against Covid-19 will get us closer to returning to normal‘ he said.

The decision is that the FDA’s Vaccines and Related Biological Products Advisory Committee recommends that the BioNTech vaccine is given to the 5-11 age group at the normal dose. 1 in 3 followed by the recommendation to implement it. On November 2-3, an independent advisory committee from the US Centers for Disease Control and Prevention (CDC) will vote on whether the vaccine should be recommended for this age group.

After the vote, CDC Director Dr. Rochelle Walensky will make the final decision on the committee’s recommendation. After Walensky signed the committee’s resolution, the United States Children between the ages of 5 and 11 will be able to start vaccinating.